Cargando…
Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients
Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4(+) T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we ident...
Autores principales: | Lu, Xiuyuan, Hosono, Yuki, Nagae, Masamichi, Ishizuka, Shigenari, Ishikawa, Eri, Motooka, Daisuke, Ozaki, Yuki, Sax, Nicolas, Maeda, Yuichi, Kato, Yasuhiro, Morita, Takayoshi, Shinnakasu, Ryo, Inoue, Takeshi, Onodera, Taishi, Matsumura, Takayuki, Shinkai, Masaharu, Sato, Takashi, Nakamura, Shota, Mori, Shunsuke, Kanda, Teru, Nakayama, Emi E., Shioda, Tatsuo, Kurosaki, Tomohiro, Takeda, Kiyoshi, Kumanogoh, Atsushi, Arase, Hisashi, Nakagami, Hironori, Yamashita, Kazuo, Takahashi, Yoshimasa, Yamasaki, Sho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641254/ https://www.ncbi.nlm.nih.gov/pubmed/34647971 http://dx.doi.org/10.1084/jem.20211327 |
Ejemplares similares
-
Tracking of activated cTfh cells following sequential influenza vaccinations reveals transcriptional profile of clonotypes driving a vaccine-induced immune response
por: Currenti, Jennifer, et al.
Publicado: (2023) -
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma
por: Byford, Elliot T., et al.
Publicado: (2018) -
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
por: Chandrakasan, Shanmuganathan, et al.
Publicado: (2022) -
The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes
por: Hill, Danika L., et al.
Publicado: (2019) -
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
por: Shinnakasu, Ryo, et al.
Publicado: (2021)